Hydroxyurea for secondary stroke prevention in children with sickle cell anemia in Nigeria: a randomized controlled trial

We tested the hypothesis that fixed oral moderate-dose hydroxyurea (20 mg/kg per day) for initial treatment of secondary stroke prevention results in an 80% relative risk reduction of stroke or death when compared with fixed oral low-dose hydroxyurea (10 mg/kg per day) in a phase 3 double-blind, par...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdullahi, Shehu U., Sunusi, Surayya, Abba, Mohammed Sani, Sani, Saifuddeen, Inuwa, Hauwau Aminu, Gambo, Safiya, Gambo, Awwal, Musa, Bilya, Covert Greene, Brittany V., Kassim, Adetola A., Rodeghier, Mark, Hussaini, Nafiu, Ciobanu, Mariana, Aliyu, Muktar H., Jordan, Lori C., DeBaun, Michael R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10023719/
https://www.ncbi.nlm.nih.gov/pubmed/36322937
http://dx.doi.org/10.1182/blood.2022016620

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10023719/
https://www.ncbi.nlm.nih.gov/pubmed/36322937
http://dx.doi.org/10.1182/blood.2022016620

Ejemplares similares